As China's economic growth declines, some analysts say Beijing may have to spend more on infrastructure, adding to concerns about high debts.China Economyread more
U.S. President Donald Trump said Tuesday that Washington and Beijing have a long way to go on trade, adding that America could place tariffs on an additional $325 billion...Asia Marketsread more
"The charts, as interpreted by Carley Garner, suggest that the upside in the stock market has gotten more limited," Jim Cramer says.Mad Money with Jim Cramerread more
John Paul Stevens, who served on the Supreme Court for nearly 35 years and became its leading liberal, has died.Politicsread more
The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
The WTO ruling recognized that the United States had proved that China used state-owned enterprises to subsidize and distort its economy. But the U.S. must accept Chinese...World Economyread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
Delta is gathering more data from customers than ever in hopes of avoiding customer service problems and increasing customer satisfaction, its CFO says.At Workread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
U.S. Surgeon General Vivek Murthy said on Tuesday he was "deeply disturbed" when he heard about Mylan's price increase of its anti-allergic reaction device EpiPen.
"My concern about drug pricing more broadly is that we have millions of people in America who are struggling to afford their medications that they require to stay healthy," Murthy told CNBC's "Power Lunch. "
"And if we really want to focus on keeping people healthy, on reducing the instances of disease complications, then we have to make sure people can get medications that are affordable prices."
Mylan was scrutinized last week after consumers saw more than a fivefold price increase for the EpiPen since 2008. The pharmaceutical company in response announced plans to increase access to its leading product by making expansions to its already existing cost-cutting programs.
The CEO, Heather Bresch, told CNBC she was "frustrated" with EpiPen's high prices and said the real problem is with the overall health care system. On Monday, the company said it would launch the first generic version of the medication at half the price.
Murthy said the recent price increase "runs counter" to efforts to keep people healthy.
He also spoke on the opioid crisis, affecting an estimated 26.4 million to 36 million people in the United States, according to the National Institute on Drug Abuse.
Murthy said the crisis is one of the U.S.'s most urgent health threats. He also said that clinicians must sharpen their subscribing practices saying in part the U.S. has not trained its medical professionals on "how to treat pain safely and effectively. "
Additionally, he urged people to think about the effect of the Zika virus.
"If we want to prevent some of the adverse outcomes related to Zika, particularly the birth defects that occur sometimes when pregnant women are impacted by Zika," he said, "then we've got to focus on prevention. We have to focus on developing a vaccine. We have to focus on mosquito control."